Pelthos Therapeutics Inc.
Income Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $16.8M | $0 |
| Cost of Revenue | $4.0M | $0 |
| Gross Profit | $12.8M | $0 |
| Gross Margin | 76.3% | — |
| Operating Expenses | ||
| Research & Development | $1.2M | $1.2M |
| SG&A Expense | $42.5M | $6.4M |
| Operating Income | $-32.4M | $-7.6M |
| Operating Margin | -193.1% | — |
| Interest Expense | — | $581.1K |
| Pretax Income | $-50.7M | $-8.0M |
| Income Tax Expense | $-7.4M | $0 |
| Net Income | $-43.3M | $-8.0M |
| Net Margin | -257.9% | — |
| EPS (Basic) | $-23.04 | $-4.76 |
| EPS (Diluted) | $-23.04 | $-4.76 |
| Shares Outstanding (Basic) | 1.9M | 1.7M |
| Shares Outstanding (Diluted) | 1.9M | 1.7M |
| Dividends Per Share | — | — |